Springvest’s H1/2026: a period of portfolio strengthening

In the first half of the year, we recognised €5.1 million in new equity holdings on the balance sheet. Our full-year target range is €5–7 million, so we reached the lower end of that target already in H1.

The carrying value of portfolio companies grew 13% year-on-year, reaching €28.2 million at the end of the period.

“This year, we discontinued our revenue and operating profit guidance. The reason is that Springvest’s value is created by the long-term development of the portfolio’s growth-stage company holdings, and we manage the company accordingly. From a value-creation perspective, the first half of 2026 was excellent,” says Springvest’s CFO Juuso Viitanen.

The most significant development for owner value this spring was strengthening the funding position of Desentum – a drug development company and the largest single holding in our portfolio. The company, now at an interesting stage of growth, raised a total of €18 million from private and family office investors during the spring.

Core business kept growing

The amount of capital arranged increased 21% year-on-year, and our fee income – received in both cash and options – grew 17%.

Three funding rounds were arranged this spring: for Desentum, augmented reality (AR) technology company Basemark, and medtech company Cerenion.

The number of Springvest shareholders also grew strongly over the half-year, up 162% to 3,721.

“One of the appealing features of the SPRING share is diversification. Where an investor in a single, direct growth-company investment carries that one company’s risk, an investment in Springvest’s share provides indirect exposure to 44 growth companies across different sectors. Our profitable core business keeps growing the portfolio and creates ongoing capacity for dividend payments,” says Springvest’s CEO Aki Soudunsaari.

Read the full half-year report and explore the figures on our investor pages!